EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access

Effect of dexmedetomidine on cerebral homeostasis in patients undergoing craniotomy for brain tumour excision: A randomized double‐blind trial

Anastasia Nikopoulou iD, Vasileios Grosomanidis, Aikaterina Poulopoulou, Timoleon-Achilleas Vyzantiadis, Chryssa Pourzitaki, Ioannis Patsalas, Georgia G Tsaousi

British Journal of Clinical Pharmacology · 2026

DOI: 10.1002/bcp.70606 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift British Journal of Clinical Pharmacology, 2026. Verfasst von Anastasia Nikopoulou und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Anesthesiology and Critical Care, Aristotle University of Thessaloniki, School of Medicine, Thessaloniki, Greece. Hauptthemen laut MEDLINE: Dexmedetomidine, Craniotomy, Brain Neoplasms, Neuroprotective Agents. Die Arbeit nennt 39 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aim

Dexmedetomidine (DEX) seems to hold a potential neuroprotective role, possibly mediated by the attenuation of oxidative stress and neuroinflammation. This study aimed to delineate the effect of DEX used as an adjunct anaesthetic on cerebral oxygenation, cerebral injury and the release of inflammatory markers in brain tumour surgery.

Methods

Fifty‐six patients undergoing craniotomy for brain tumour excision were randomly assigned to receive either DEX (1 μg/kg for 10 min and thereafter 0.7 μg/kg/h) or placebo. Arterial and jugular‐bulb blood samples were collected at predefined time‐points, whereas a concomitant hemodynamic profile was obtained intraoperatively. S100B protein, neuron‐specific enolase (NSE), tumour necrosis factor‐α (TNF‐α), interleukin‐6 (IL‐6) and cortisol levels were determined at baseline and 6 and 24 h postoperatively.

Results

Demographic and perioperative characteristics were comparable between groups. Propofol consumption was considerably reduced in DEX‐treated patients ( p < 0.001). Measured (jugular‐bulb oxygen saturation and partial pressure of oxygen) and estimated (oxygen and carbon dioxide arterial‐jugular differences, brain oxygen extraction ratio) cerebral oxygenation indices were favourably affected by DEX infusion ( p < 0.05), yet this effect was valid for 15 min ( p < 0.05), corresponding to transient systemic hemodynamic augmentation. Moreover, postoperative S100B, NSE, TNF‐α, IL‐6 and cortisol levels were significantly attenuated in the DEX group ( p < 0.01).

Conclusion

DEX may attenuate the release of cerebral injury and neuroinflammation biomarkers and transiently improve hemodynamics and cerebral oxygenation during brain tumour surgery. Nonetheless, these surrogate effects do not establish clinically relevant neuroprotection, and potential dose‐related hemodynamic instability warrants cautious, individualized use.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

DexmedetomidineCraniotomyBrain NeoplasmsNeuroprotective AgentsHumansFemaleMaleDouble-Blind MethodMiddle AgedHomeostasisAdultS100 Calcium Binding Protein beta SubunitTumor Necrosis Factor-alphaNeuroanesthesiaAged

Stichwörter der Autor:innen

cerebral oxygenationcraniotomydexmedetomidinehemodynamicsneuroinflammationneuroprotection

Substanzen

DexmedetomidineNeuroprotective AgentsS100 Calcium Binding Protein beta SubunitTumor Necrosis Factor-alpha

Autor:innen und Institutionen

  • Department of Anesthesiology and Critical Care, Aristotle University of Thessaloniki, School of Medicine, Thessaloniki, Greece.
  • 1st Department of Microbiology, Aristotle University of Thessaloniki, School of Medicine, Thessaloniki, Greece.
  • Laboratory of Clinical Pharmacology, Aristotle University of Thessaloniki, School of Medicine, Thessaloniki, Greece.
  • Department of Neurosurgery, Aristotle University of Thessaloniki, School of Medicine, Thessaloniki, Greece.

ORCID-Profile: Anastasia Nikopoulou

Zitieren

APA

Nikopoulou, A., Grosomanidis, V., Poulopoulou, A., Vyzantiadis, T. A., Pourzitaki, C., Patsalas, I., & Tsaousi, G. G. (2026). Effect of dexmedetomidine on cerebral homeostasis in patients undergoing craniotomy for brain tumour excision: A randomized double‐blind trial. British Journal of Clinical Pharmacology. https://doi.org/10.1002/bcp.70606

Vancouver

Nikopoulou A, Grosomanidis V, Poulopoulou A, Vyzantiadis TA, Pourzitaki C, Patsalas I, et al. Effect of dexmedetomidine on cerebral homeostasis in patients undergoing craniotomy for brain tumour excision: A randomized double‐blind trial. British Journal of Clinical Pharmacology. 2026. doi:10.1002/bcp.70606

BibTeX
@article{Nikopoulou2026,
  author = {Nikopoulou, Anastasia and Grosomanidis, Vasileios and Poulopoulou, Aikaterina and Vyzantiadis, Timoleon-Achilleas and Pourzitaki, Chryssa and Patsalas, Ioannis and Tsaousi, Georgia G},
  title = {Effect of dexmedetomidine on cerebral homeostasis in patients undergoing craniotomy for brain tumour excision: A randomized double‐blind trial},
  journal = {British Journal of Clinical Pharmacology},
  year = {2026},
  doi = {10.1002/bcp.70606}
}
Kostenlos starten →